Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Decreased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 54.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 45,821 shares of the company's stock after selling 55,413 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Moderna were worth $1,839,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Intrinsic Value Partners LLC raised its holdings in Moderna by 91.1% in the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company's stock valued at $3,435,000 after acquiring an additional 24,505 shares in the last quarter. Banco Santander S.A. acquired a new stake in Moderna in the third quarter valued at $3,550,000. John G Ullman & Associates Inc. raised its holdings in Moderna by 341.3% in the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company's stock valued at $3,318,000 after acquiring an additional 38,400 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company's stock valued at $107,885,000 after acquiring an additional 167,596 shares in the last quarter. Finally, abrdn plc increased its stake in Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company's stock valued at $12,842,000 after purchasing an additional 69,360 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. HSBC upgraded shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 price target on the stock in a research report on Monday, November 18th. Leerink Partners reduced their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research report on Thursday, January 16th. Argus downgraded shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Sanford C. Bernstein assumed coverage on shares of Moderna in a research report on Thursday, October 17th. They issued a "market perform" rating and a $55.00 price target on the stock. Finally, Berenberg Bank raised their price target on shares of Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $66.89.

Moderna Price Performance

Shares of MRNA stock traded up $1.07 during midday trading on Friday, reaching $32.99. 25,297,536 shares of the company were exchanged, compared to its average volume of 12,858,421. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The company has a market cap of $12.70 billion, a P/E ratio of -5.67 and a beta of 1.59. The company's 50 day moving average price is $39.09 and its two-hundred day moving average price is $55.77. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company's stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.